Measuring brain amyloid levels in Alzheimer's patients
UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy
PHASE2 · University of Alabama at Birmingham · NCT03503331
This study is testing how amyloid levels in the brains of people with Alzheimer's relate to their health and background to see if early brain scans can help predict memory problems.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 160 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | University of Alabama at Birmingham (other) |
| Locations | 1 site (Birmingham, Alabama) |
| Trial ID | NCT03503331 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the concentration and distribution of amyloid deposits in the brain using the PET tracer [C-11]PiB among participants in the UAB Alzheimer's Disease Center cohort. It will correlate amyloid levels with demographic, clinical, genetic, and biospecimen data from an ongoing study. Additionally, the study will evaluate how race and vascular risk factors interact with brain amyloid levels and cognitive status. A secondary goal is to determine if early imaging results can predict cognitive decline.
Who should consider this trial
Good fit: Ideal candidates are individuals enrolled in the UAB-ADC study who are undergoing assessment for Alzheimer's disease.
Not a fit: Patients with severe dementia or those unable to undergo MRI or PET imaging may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of Alzheimer's disease progression and improve diagnostic methods.
How similar studies have performed: Other studies using PET imaging to assess amyloid deposition have shown promising results, indicating this approach is supported by prior research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- 1. Enrollment in the UAB-ADC study under a separate IRB-approved research protocol (IRB-300000169). 2\. Negative urine or serum B-hCG test within 2 days of \[C-11\]PiB administration in women of child bearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing. Exclusion Criteria: 1. Meets any exclusion criteria for the UAB-ADC study (IRB-300000169). 2. Inability or contraindication for undergoing MRI and/or PET imaging 3. Inability to participate in the imaging studies due to severity of dementia
Where this trial is running
Birmingham, Alabama
- University of Alabama at Birmingham Medical Center — Birmingham, Alabama, United States (RECRUITING)
Study contacts
- Principal investigator: Jonathan McConathy, MD — University of Alabama at Birmingham
- Study coordinator: Chinara Dosse
- Email: cdosse@uabmc.edu
- Phone: (205) 975-7017
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Alzheimer Disease